{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:40:07Z","timestamp":1795095607725,"version":"4.10.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) are proteins essential for neuronal survival and implicated in Parkinson\u2019s disease (PD) pathophysiology. Although reduced levels of these neurotrophins have been observed in PD, their relationship with disease progression remains unclear. We conducted a systematic review by independently searching four databases using predefined keywords: Parkinson AND (GDNF OR BDNF OR neurotroph) AND (serum OR blood OR cerebrospinal fluid). After screening 2132 records, 35 studies qualified for inclusion. Changes in neurotrophic factors\u2019 levels were evaluated in relation to disease severity and duration. Many studies reported a decline in BDNF levels associated with more severe motor symptoms. Some studies noted increased BDNF levels in advanced PD. This pattern may be affected by levodopa treatment, suggesting that elevated BDNF levels in advanced PD could reflect a treatment-related effect rather than disease progression itself. Reduced levels of both GDNF and BDNF were linked to cognitive decline, with BDNF also decreased in PD patients with depression. Serum BDNF levels were associated with motor severity and neuropsychiatric symptoms. BDNF levels in PD may increase with longer disease duration, likely due to levodopa treatment effects. However, lower BDNF levels are seen in cognitive decline and depression, frequent non-motor symptoms of PD. Further research is required to clarify BDNF dynamics and to determine GDNF\u2019s role in motor progression and cognitive decline.<\/jats:p>","DOI":"10.1007\/s12035-025-05649-z","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:47:01Z","timestamp":1771220821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BDNF and GDNF in Parkinson\u2019s Disease: Associations with Clinical Features, Disease Course, and Progression\u2014A Systematic Review"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7458-2856","authenticated-orcid":false,"given":"Julia","family":"W\u0119grzynek-Gallina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7534-7830","authenticated-orcid":false,"given":"Aleksandra","family":"Buczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-1487","authenticated-orcid":false,"given":"Jakub","family":"Malkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-7731","authenticated-orcid":false,"given":"Tomasz","family":"Chmiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-4354","authenticated-orcid":false,"given":"Tomasz","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5881-0733","authenticated-orcid":false,"given":"Patrycja","family":"Hudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-660X","authenticated-orcid":false,"given":"Joanna","family":"Siuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"5649_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/padi\/6691390","author":"S Caproni","year":"2025","unstructured":"Caproni S, Di Fonzo A, Colosimo C (2025) Oxidative stress: a new pathophysiological pathway in Parkinson\u2019s disease and a potential target of the brain-sport crosstalk. Parkinsons Dis. https:\/\/doi.org\/10.1155\/padi\/6691390","journal-title":"Parkinsons Dis"},{"key":"5649_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1590\/0004-282x20180035","volume":"76","author":"NP Rocha","year":"2018","unstructured":"Rocha NP, Ferreira JPS, Scalzo PL et al (2018) Circulating levels of neurotrophic factors are unchanged in patients with Parkinson\u2019s disease. Arq Neuropsiquiatr 76:310\u2013315. https:\/\/doi.org\/10.1590\/0004-282x20180035","journal-title":"Arq Neuropsiquiatr"},{"key":"5649_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10090684","author":"CC Chung","year":"2020","unstructured":"Chung CC, Huang PH, Chan L et al (2020) Plasma exosomal brain-derived neurotrophic factor correlated with the postural instability and gait disturbance\u2013related motor symptoms in patients with Parkinson\u2019s disease. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics10090684","journal-title":"Diagnostics"},{"key":"5649_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2024.1370787","volume":"18","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xu Y, Tong SY (2024) Serum glial cell line-derived neurotrophic factor: a potential biomarker for white matter alteration in Parkinson\u2019s disease with mild cognitive impairment. Front Neurosci 18:1\u201310. https:\/\/doi.org\/10.3389\/fnins.2024.1370787","journal-title":"Front Neurosci"},{"key":"5649_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JPD-202004","volume":"10","author":"RA Barker","year":"2020","unstructured":"Barker RA, Bj\u00f6rklund A, Gash DM et al (2020) GDNF and Parkinson\u2019s disease: where next? A summary from a recent workshop. J Parkinsons Dis 10:875\u2013891. https:\/\/doi.org\/10.3233\/JPD-202004","journal-title":"J Parkinsons Dis"},{"key":"5649_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00415-009-5357-2","volume":"257","author":"P Scalzo","year":"2010","unstructured":"Scalzo P, K\u00fcmmer A, Bretas TL et al (2010) Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson\u2019s disease. J Neurol 257:540\u2013545. https:\/\/doi.org\/10.1007\/s00415-009-5357-2","journal-title":"J Neurol"},{"key":"5649_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577545","volume":"354","author":"A Roy","year":"2021","unstructured":"Roy A, Mondal B, Banerjee R et al (2021) Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson\u2019s disease? J Neuroimmunol 354:577545. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577545","journal-title":"J Neuroimmunol"},{"key":"5649_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.05.023","volume":"29","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu H, Zhang BS et al (2016) Low BDNF is associated with cognitive impairments in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 29:66\u201371. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.023","journal-title":"Parkinsonism Relat Disord"},{"key":"5649_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.17219\/acem\/154955","volume":"32","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zhang H (2023) A meta-analysis on the role of brain-derived neurotrophic factor in Parkinson\u2019s disease patients. Adv Clin Exp Med 32:285\u2013295. https:\/\/doi.org\/10.17219\/acem\/154955","journal-title":"Adv Clin Exp Med"},{"key":"5649_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jocn.2019.01.017","volume":"63","author":"Y Huang","year":"2019","unstructured":"Huang Y, Huang C, Yun W (2019) Peripheral BDNF\/TrkB protein expression is decreased in Parkinson\u2019s disease but not in essential tremor. J Clin Neurosci 63:176\u2013181. https:\/\/doi.org\/10.1016\/j.jocn.2019.01.017","journal-title":"J Clin Neurosci"},{"key":"5649_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00702-024-02802-1","volume":"131","author":"X Wang","year":"2024","unstructured":"Wang X, Zhou C, Li Y et al (2024) Sex-dependent associations of serum BDNF, glycolipid metabolism and cognitive impairments in Parkinson\u2019s disease with depression: a comprehensive analysis. J Neural Transm 131:1047\u20131057. https:\/\/doi.org\/10.1007\/s00702-024-02802-1","journal-title":"J Neural Transm"},{"key":"5649_CR12","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00415-020-10299-3","volume":"268","author":"Y Huang","year":"2021","unstructured":"Huang Y, Huang C, Zhang Q et al (2021) Serum BDNF discriminates Parkinson\u2019s disease patients with depression from without depression and reflect motor severity and gender differences. J Neurol 268:1411\u20131418. https:\/\/doi.org\/10.1007\/s00415-020-10299-3","journal-title":"J Neurol"},{"key":"5649_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2023.1136499","volume":"17","author":"SY Tong","year":"2023","unstructured":"Tong SY, Wang RW, Li Q et al (2023) Serum glial cell line-derived neurotrophic factor (GDNF) a potential biomarker of executive function in Parkinson\u2019s disease. Front Neurosci 17:1\u20139. https:\/\/doi.org\/10.3389\/fnins.2023.1136499","journal-title":"Front Neurosci"},{"key":"5649_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4103\/1673-5374.297091","volume":"16","author":"MY Shi","year":"2021","unstructured":"Shi MY, Ma CC, Chen FF et al (2021) Possible role of glial cell line-derived neurotrophic factor for predicting cognitive impairment in Parkinson\u2019s disease: a case-control study. Neural Regen Res 16:885\u2013892. https:\/\/doi.org\/10.4103\/1673-5374.297091","journal-title":"Neural Regen Res"},{"key":"5649_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14030194","author":"DGM Kaagman","year":"2024","unstructured":"Kaagman DGM, van Wegen EEH, Cignetti N et al (2024) Effects and mechanisms of exercise on brain-derived neurotrophic factor (BDNF) levels and clinical outcomes in people with Parkinson\u2019s disease: a systematic review and meta-analysis. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci14030194","journal-title":"Brain Sci"},{"key":"5649_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainres.2018.10.006","volume":"1704","author":"F Rahmani","year":"2019","unstructured":"Rahmani F, Saghazadeh A, Rahmani M et al (2019) Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res 1704:127\u2013136. https:\/\/doi.org\/10.1016\/j.brainres.2018.10.006","journal-title":"Brain Res"},{"key":"5649_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2024.1352305","volume":"15","author":"A Paterno","year":"2024","unstructured":"Paterno A, Polsinelli G, Federico B (2024) Changes of brain-derived neurotrophic factor (BDNF) levels after different exercise protocols: a systematic review of clinical studies in Parkinson\u2019s disease. Front Physiol 15:1\u201313. https:\/\/doi.org\/10.3389\/fphys.2024.1352305","journal-title":"Front Physiol"},{"key":"5649_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2021.645583","volume":"13","author":"PA Kambey","year":"2021","unstructured":"Kambey PA, Kanwore K, Ayanlaja AA et al (2021) Failure of glial cell-line derived neurotrophic factor (GDNF) in clinical trials orchestrated by reduced NR4A2 (NURR1) transcription factor in Parkinson\u2019s disease. A Syst Rev Front Aging Neurosci 13:1\u201315. https:\/\/doi.org\/10.3389\/fnagi.2021.645583","journal-title":"A systematic review Front Aging Neurosci"},{"key":"5649_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178\u2013189. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.03.001","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"5649_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.7202\/1071537ar","volume":"3","author":"K Crombie","year":"2005","unstructured":"Crombie K (2005) Ottawa. Fr Am Cult Polit Hist 3(3):900\u2013902. https:\/\/doi.org\/10.7202\/1071537ar","journal-title":"Fr Am Cult Polit Hist"},{"key":"5649_CR21","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210.\u00a0https:\/\/doi.org\/10.1186\/s13643-016-0384-4. Accessed 9 Jan 2026","DOI":"10.1186\/s13643-016-0384-4"},{"key":"5649_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106371","volume":"190","author":"G Di Lazzaro","year":"2024","unstructured":"Di Lazzaro G, Picca A, Boldrini S et al (2024) Differential profiles of serum cytokines in Parkinson\u2019s disease according to disease duration. Neurobiol Dis 190:106371. https:\/\/doi.org\/10.1016\/j.nbd.2023.106371","journal-title":"Neurobiol Dis"},{"key":"5649_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1177\/0300060517748843","volume":"46","author":"Y Huang","year":"2018","unstructured":"Huang Y, Yun W, Zhang M et al (2018) Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson\u2019s disease or essential tremor. J Int Med Res 46:1477\u20131485. https:\/\/doi.org\/10.1177\/0300060517748843","journal-title":"J Int Med Res"},{"key":"5649_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.734570","volume":"12","author":"YX Huang","year":"2021","unstructured":"Huang YX, Zhang QL, Huang CL et al (2021) Association of decreased serum BDNF with restless legs syndrome in Parkinson\u2019s disease patients. Front Neurol 12:1\u20138. https:\/\/doi.org\/10.3389\/fneur.2021.734570","journal-title":"Front Neurol"},{"key":"5649_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.680765","volume":"12","author":"X Yi","year":"2021","unstructured":"Yi X, Yang Y, Zhao Z et al (2021) Serum mBDNF and ProBDNF expression levels as diagnosis clue for early stage Parkinson\u2019s disease. Front Neurol 12:1\u20136. https:\/\/doi.org\/10.3389\/fneur.2021.680765","journal-title":"Front Neurol"},{"key":"5649_CR26","doi-asserted-by":"publisher","unstructured":"Ekmekyapar T, T\u00fcrk\u00f6z Y, Erdemli Z et al (2021) Relationships between parkinson\u2019s disease dementia and 25-hydroxy vitamin d and brain-derived neurotrophic factor levels. Turk Geriatr Derg 24:407\u2013415. https:\/\/doi.org\/10.31086\/tjgeri.2021.238","DOI":"10.31086\/tjgeri.2021.238"},{"key":"5649_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2017.05.012","volume":"41","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu H, Du XD et al (2017) Association of low serum BDNF with depression in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 41:73\u201378. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.05.012","journal-title":"Parkinsonism Relat Disord"},{"key":"5649_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/901082","author":"M Ventriglia","year":"2013","unstructured":"Ventriglia M, Zanardini R, Bonomini C et al (2013) Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int. https:\/\/doi.org\/10.1155\/2013\/901082","journal-title":"Biomed Res Int"},{"key":"5649_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/JCP.0b013e3181fc2ec7","volume":"30","author":"V Ricci","year":"2010","unstructured":"Ricci V, Pomponi M, Martinotti G et al (2010) Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in parkinson disease patients. J Clin Psychopharmacol 30:751\u2013753. https:\/\/doi.org\/10.1097\/JCP.0b013e3181fc2ec7","journal-title":"J Clin Psychopharmacol"},{"key":"5649_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pjnns.2016.10.001","volume":"51","author":"J Siuda","year":"2017","unstructured":"Siuda J, Patalong-Ogiewa M, \u017bmuda W et al (2017) Cognitive impairment and BDNF serum levels. Neurol Neurochir Pol 51:24\u201332. https:\/\/doi.org\/10.1016\/j.pjnns.2016.10.001","journal-title":"Neurol Neurochir Pol"},{"key":"5649_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00415-009-5353-6","volume":"257","author":"S P\u00e5lhagen","year":"2010","unstructured":"P\u00e5lhagen S, Qi H, M\u00e5rtensson B et al (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson\u2019s disease and major depression. J Neurol 257:524\u2013532. https:\/\/doi.org\/10.1007\/s00415-009-5353-6","journal-title":"J Neurol"},{"key":"5649_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-023-00662-2","author":"MY Badr","year":"2023","unstructured":"Badr MY, Amer RA, Kotait MA et al (2023) Role of multimodal advanced biomarkers as potential predictors of cognitive and psychiatric aspects of Parkinson\u2019s disease. Egypt J Neurol Psychiatry Neurosurg. https:\/\/doi.org\/10.1186\/s41983-023-00662-2","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"5649_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnbeh.2015.00253","volume":"9","author":"A Costa","year":"2015","unstructured":"Costa A, Peppe A, Carlesimo GA et al (2015) Brain-derived neurotrophic factor serum levels correlate with cognitive performance in parkinson\u2019s disease patients with mild cognitive impairment. Front Behav Neurosci 9:1\u20138. https:\/\/doi.org\/10.3389\/fnbeh.2015.00253","journal-title":"Front Behav Neurosci"},{"key":"5649_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jns.2016.01.032","volume":"362","author":"H Khalil","year":"2016","unstructured":"Khalil H, Alomari MA, Khabour OF et al (2016) Relationship of circulatory BDNF with cognitive deficits in people with Parkinson\u2019s disease. J Neurol Sci 362:217\u2013220. https:\/\/doi.org\/10.1016\/j.jns.2016.01.032","journal-title":"J Neurol Sci"},{"key":"5649_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.parkreldis.2010.10.003","volume":"17","author":"JB Leverenz","year":"2011","unstructured":"Leverenz JB, Stennis Watson G, Shofer J et al (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 17:61\u201364. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.10.003","journal-title":"Parkinsonism Relat Disord"},{"key":"5649_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cns.14461","volume":"30","author":"C Tang","year":"2024","unstructured":"Tang C, Sun R, Xue K et al (2024) Distinct serum GDNF coupling with brain structural and functional changes underlies cognitive status in Parkinson\u2019s disease. CNS Neurosci Ther 30:1\u201317. https:\/\/doi.org\/10.1111\/cns.14461","journal-title":"CNS Neurosci Ther"},{"key":"5649_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/gps.5222","volume":"35","author":"Y Liu","year":"2020","unstructured":"Liu Y, Tong S, Ding L et al (2020) Serum levels of glial cell line-derived neurotrophic factor and multiple neurotransmitters: in relation to cognitive performance in Parkinson\u2019s disease with mild cognitive impairment. Int J Geriatr Psychiatry 35:153\u2013162. https:\/\/doi.org\/10.1002\/gps.5222","journal-title":"Int J Geriatr Psychiatry"},{"key":"5649_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13020200","author":"L Wang","year":"2023","unstructured":"Wang L, Gao Z, Chen G et al (2023) Low levels of adenosine and GDNF are potential risk factors for Parkinson\u2019s disease with sleep disorders. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci13020200","journal-title":"Brain Sci"},{"key":"5649_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137380","author":"H Jin","year":"2023","unstructured":"Jin H, Shen H, Liu C et al (2023) Decreased serum BDNF contributes to the onset of REM sleep behavior disorder in Parkinson\u2019s disease patients. Neurosci Lett. https:\/\/doi.org\/10.1016\/j.neulet.2023.137380","journal-title":"Neurosci Lett"},{"key":"5649_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.sleep.2021.11.018","volume":"90","author":"M Kaminska","year":"2022","unstructured":"Kaminska M, O\u2019Sullivan M, Mery VP et al (2022) Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson\u2019s disease (PD). Sleep Med 90:258\u2013261. https:\/\/doi.org\/10.1016\/j.sleep.2021.11.018","journal-title":"Sleep Med"},{"key":"5649_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.777591","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, Du Y, Li X et al (2022) Lower GDNF serum level is a possible risk factor for constipation in patients with Parkinson disease: a case\u2013control study. Front Neurol 12:1\u201312. https:\/\/doi.org\/10.3389\/fneur.2021.777591","journal-title":"Front Neurol"},{"key":"5649_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.26650\/experimed.1472096","volume":"14","author":"ND Korkmaz","year":"2024","unstructured":"Korkmaz ND, Elibol B, Susgun S et al (2024) Relationship between BDNF and LPS levels in the blood of patients with different neurological diseases: a small cohort study. Experimed 14:92\u2013101. https:\/\/doi.org\/10.26650\/experimed.1472096","journal-title":"Experimed"},{"key":"5649_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121144","volume":"311","author":"MA Alomari","year":"2022","unstructured":"Alomari MA, Khalil H, Khabour OF, Alzoubi KH (2022) Lipid profile in Parkinson\u2019s disease: the potential role of brain-derived neurotrophic factor. Life Sci 311:121144. https:\/\/doi.org\/10.1016\/j.lfs.2022.121144","journal-title":"Life Sci"},{"key":"5649_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/0361073X.2018.1449589","volume":"44","author":"MA Alomari","year":"2018","unstructured":"Alomari MA, Khalil H, Khabour OF et al (2018) Altered cardiovascular function is related to reduced BDNF in Parkinson\u2019s disease. Exp Aging Res 44:232\u2013245. https:\/\/doi.org\/10.1080\/0361073X.2018.1449589","journal-title":"Exp Aging Res"},{"key":"5649_CR45","doi-asserted-by":"publisher","first-page":"428.e1","DOI":"10.1016\/j.neurobiolaging.2010.11.010","volume":"33","author":"M Ziebell","year":"2012","unstructured":"Ziebell M, Khalid U, Klein AB et al (2012) Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol Aging 33:428.e1-428.e5. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.11.010","journal-title":"Neurobiol Aging"},{"key":"5649_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.brainres.2006.04.019","volume":"1095","author":"X Zhang","year":"2006","unstructured":"Zhang X, Andren PE, Svenningsson P (2006) Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson\u2019s disease. Brain Res 1095:207\u2013210. https:\/\/doi.org\/10.1016\/j.brainres.2006.04.019","journal-title":"Brain Res"},{"key":"5649_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2010.01.013","volume":"291","author":"K Ohta","year":"2010","unstructured":"Ohta K, Kuno S, Inoue S et al (2010) The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci 291:12\u201316. https:\/\/doi.org\/10.1016\/j.jns.2010.01.013","journal-title":"J Neurol Sci"},{"key":"5649_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12868-018-0478-0","volume":"19","author":"S Leino","year":"2018","unstructured":"Leino S, Kohtala S, Rantam\u00e4ki T et al (2018) Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation. BMC Neurosci 19:1\u201310. https:\/\/doi.org\/10.1186\/s12868-018-0478-0","journal-title":"BMC Neurosci"},{"key":"5649_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/NRR.NRR-D-23-01419","volume":"20","author":"M Han","year":"2023","unstructured":"Han M, Zeng D, Tan W et al (2023) Brain region-specific roles of brain-derived neurotrophic factor in social stress-induced depressive-like behavior. Neural Regen Res 20:159\u2013173. https:\/\/doi.org\/10.4103\/NRR.NRR-D-23-01419","journal-title":"Neural Regen Res"},{"key":"5649_CR50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1523\/JNEUROSCI.3082-12.2013","volume":"33","author":"X Li","year":"2013","unstructured":"Li X, De Joseph MR, Urban JH et al (2013) Different roles of BDNF in nucleus accumbens core versus shell during the incubation of cue-induced cocaine craving and its long-term maintenance. J Neurosci 33:1130\u20131142. https:\/\/doi.org\/10.1523\/JNEUROSCI.3082-12.2013","journal-title":"J Neurosci"},{"key":"5649_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jad.2014.11.044","volume":"174","author":"M Polyakova","year":"2015","unstructured":"Polyakova M, Stuke K, Schuemberg K et al (2015) BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 174:432\u2013440. https:\/\/doi.org\/10.1016\/j.jad.2014.11.044","journal-title":"J Affect Disord"},{"key":"5649_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tp.2017.43","volume":"7","author":"H Jiang","year":"2017","unstructured":"Jiang H, Chen S, Li C et al (2017) The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment. Transl Psychiatry 7:1\u20135. https:\/\/doi.org\/10.1038\/tp.2017.43","journal-title":"Transl Psychiatry"},{"key":"5649_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/0361073X.2018.1449589","volume":"14","author":"S P\u00e5lhagen","year":"2024","unstructured":"P\u00e5lhagen S, Qi H, M\u00e5rtensson B et al (2024) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson\u2019s disease and major depression. J Neurol 14:232\u2013245. https:\/\/doi.org\/10.1080\/0361073X.2018.1449589","journal-title":"J Neurol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05649-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:08:22Z","timestamp":1771430902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05649-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5649"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05649-z","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this study, as it did not involve human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"440"}}